Gossamer Bio, Inc. - 8-K Filing
Gossamer Bio submitted its first NDA to the FDA for seralutinib in PAH on September 23, 2026. (Items: 8.01 Other Events)
Tickers: $GOSS
Gossamer Bio submitted its first NDA to the FDA for seralutinib in PAH on September 23, 2026. (Items: 8.01 Other Events)
Tickers: $GOSS